Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
Earnings Data
Report Date
Apr 29, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.78Last Year’s EPS
0.95Same Quarter Last Year
Moderate Buy
Based on 18 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a largely positive commercial and operational performance: record revenues, strong YOY growth for Voxzogo and enzyme therapies, improved profitability (non-GAAP EPS and operating cash flow), clear near-term R&D catalysts, and strategic acquisitions that should expand the portfolio and future revenues. Headwinds were acknowledged and quantified — notably the Roctavian withdrawal and related charges, one-time Q4 order timing effects leading to a weaker Q1, lower royalty expectations, routine market-access renegotiations in select countries, and modest near-term dilution and costs tied to the Amicus acquisition. Management provided concrete 2026 guidance (excluding Amicus post-close contributions) and explained assumptions for competitive scenarios. Overall, positives (robust growth, cash generation, pipeline catalysts, and strategic M&A) outweigh the defined near-term and one-time negatives.Company Guidance
Record Annual Revenue and Strong Top-Line Growth
Total 2025 revenues grew 13% year-over-year to a record $3.22 billion; Q4 2025 revenue was $875 million, up 17% YoY.
Voxzogo Rapid Expansion
Voxzogo revenue increased 26% for full year 2025 to $927 million and 31% in Q4; ~73% (~$680 million) of Voxzogo revenue was generated outside the U.S.; over 5,000 children treated worldwide by year-end.
Enzyme Therapies Durability and Growth
Full-year enzyme therapies revenue rose 9% in 2025 (Q4 +13% YoY), with the franchise described as a $2B+ business across an 80-country footprint.
Palynziq Outperformance and Regulatory Momentum
Palynziq revenue grew 22% for the year and 25% in Q4; an adolescent-label expansion has a U.S. PDUFA target action date of February 28, 2026, which management expects to drive additional uptake.
Profitability and Cash Flow Improvement
Reported full-year 2025 non-GAAP diluted EPS was $3.15; underlying business EPS (excluding IPR&D and Roctavian charges) grew approximately 34%; operating cash flow was $828 million, a 45% increase versus 2024.
2026 Guidance (Excluding Amicus Post-Close Contributions)
2026 guidance: enzyme therapies $2.225B–$2.275B; Voxzogo $975M–$1.025B; total revenues $3.325B–$3.425B; non-GAAP diluted EPS $4.95–$5.15; underlying organic operating margin ~40% (pre-Amicus).
Pipeline and R&D Milestones
Multiple near-term milestones: Phase III readouts planned for Voxzogo hypochondroplasia and BMN 401 (ENPP1 deficiency); BMN 333 Phase II/III initiation with Phase III powered (60 patients/arm) to detect a 50% increase in annualized growth velocity (2.25 cm/year over placebo); BMN 351 showed 5% mean absolute dystrophin at week 25 (9 mg/kg), predicting ~10% at steady state and additional cohorts enrolling.
Strategic Acquisitions and Financing
Inozyme acquisition adds BMN 401 (ENPP1 deficiency); Amicus acquisition (Galafold, Pombiliti, Opfolda) expected to close Q2 2026 and is projected to meaningfully uplift 2026+ revenues; secured approximately $3.7 billion of debt financing to support the Amicus transaction with favorable pricing.
Commercial Execution and International Penetration
Examples of commercial execution include ~40% penetration within 7 months in an Asia Pacific launch and ~70% penetration within 12 months in a midsized European country; management emphasizes focus on infants (0–2) and expanding in fast-growing ex-U.S. markets (≈75% of Voxzogo revenues ex-U.S.).
BMRN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BMRN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 23, 2026 | $62.92 | $62.62 | -0.48% |
Oct 27, 2025 | $52.67 | $53.49 | +1.56% |
Aug 04, 2025 | $60.31 | $61.93 | +2.69% |
May 01, 2025 | $62.71 | $62.03 | -1.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioMarin Pharmaceutical (BMRN) report earnings?
BioMarin Pharmaceutical (BMRN) is schdueled to report earning on Apr 29, 2026, After Close (Confirmed).
What is BioMarin Pharmaceutical (BMRN) earnings time?
BioMarin Pharmaceutical (BMRN) earnings time is at Apr 29, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BMRN EPS forecast?
BMRN EPS forecast for the fiscal quarter 2026 (Q1) is 0.78.
